These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29316528)

  • 21. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.
    Ossenkoppele R; Mattsson N; Teunissen CE; Barkhof F; Pijnenburg Y; Scheltens P; van der Flier WM; Rabinovici GD
    Neurobiol Aging; 2015 Aug; 36(8):2340-7. PubMed ID: 25990306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease.
    Dicks E; van der Flier WM; Scheltens P; Barkhof F; Tijms BM;
    Neurobiol Aging; 2020 Oct; 94():71-80. PubMed ID: 32585492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels.
    Molinuevo JL; Ripolles P; Simó M; Lladó A; Olives J; Balasa M; Antonell A; Rodriguez-Fornells A; Rami L
    Neurobiol Aging; 2014 Dec; 35(12):2671-2680. PubMed ID: 25002037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease.
    McDonough IM; Bischof GN; Kennedy KM; Rodrigue KM; Farrell ME; Park DC
    Neurobiol Aging; 2016 Oct; 46():68-75. PubMed ID: 27460151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.
    Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR
    Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gray matter network disruptions and amyloid beta in cognitively normal adults.
    Tijms BM; Kate MT; Wink AM; Visser PJ; Ecay M; Clerigue M; Estanga A; Garcia Sebastian M; Izagirre A; Villanua J; Martinez Lage P; van der Flier WM; Scheltens P; Sanz Arigita E; Barkhof F
    Neurobiol Aging; 2016 Jan; 37():154-160. PubMed ID: 26559882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas.
    Fortea J; Sala-Llonch R; Bartrés-Faz D; Lladó A; Solé-Padullés C; Bosch B; Antonell A; Olives J; Sanchez-Valle R; Molinuevo JL; Rami L
    Biol Psychiatry; 2011 Jul; 70(2):183-90. PubMed ID: 21514924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma β-amyloid in Alzheimer's disease and vascular disease.
    Janelidze S; Stomrud E; Palmqvist S; Zetterberg H; van Westen D; Jeromin A; Song L; Hanlon D; Tan Hehir CA; Baker D; Blennow K; Hansson O
    Sci Rep; 2016 May; 6():26801. PubMed ID: 27241045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Individual Correspondence of Amyloid-β and Intrinsic Connectivity in the Posterior Default Mode Network Across Stages of Alzheimer's Disease.
    Pasquini L; Benson G; Grothe MJ; Utz L; Myers NE; Yakushev I; Grimmer T; Scherr M; Sorg C;
    J Alzheimers Dis; 2017; 58(3):763-773. PubMed ID: 28482640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
    Lautner R; Insel PS; Skillbäck T; Olsson B; Landén M; Frisoni GB; Herukka SK; Hampel H; Wallin A; Minthon L; Hansson O; Blennow K; Mattsson N; Zetterberg H
    Alzheimers Res Ther; 2017 Oct; 9(1):87. PubMed ID: 29061195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Beta-Amyloid on Resting State Functional Connectivity Within and Between Networks Reflect Known Patterns of Regional Vulnerability.
    Elman JA; Madison CM; Baker SL; Vogel JW; Marks SM; Crowley S; O'Neil JP; Jagust WJ
    Cereb Cortex; 2016 Feb; 26(2):695-707. PubMed ID: 25405944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered whole-brain white matter networks in preclinical Alzheimer's disease.
    Fischer FU; Wolf D; Scheurich A; Fellgiebel A;
    Neuroimage Clin; 2015; 8():660-6. PubMed ID: 26288751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls.
    Mattsson N; Insel PS; Donohue M; Jagust W; Sperling R; Aisen P; Weiner MW;
    JAMA Neurol; 2015 May; 72(5):554-60. PubMed ID: 25775167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-β levels.
    Arenaza-Urquijo EM; Molinuevo JL; Sala-Llonch R; Solé-Padullés C; Balasa M; Bosch B; Olives J; Antonell A; Lladó A; Sánchez-Valle R; Rami L; Bartrés-Faz D
    J Alzheimers Dis; 2013; 35(4):715-26. PubMed ID: 23481686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered Gray Matter Structural Covariance Networks in Early Stages of Alzheimer's Disease.
    Montembeault M; Rouleau I; Provost JS; Brambati SM;
    Cereb Cortex; 2016 Jun; 26(6):2650-62. PubMed ID: 25994962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.